Arcus Biosciences, Inc. (RCUS) News

Arcus Biosciences, Inc. (RCUS): $16.97

0.03 (-0.18%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add RCUS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#74 of 351

in industry

Filter RCUS News Items

RCUS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RCUS News Highlights

  • For RCUS, its 30 day story count is now at 4.
  • Over the past 6 days, the trend for RCUS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about RCUS are EXEL and PHVS.

Latest RCUS News From Around the Web

Below are the latest news stories about ARCUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RCUS as an investment opportunity.

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., December 11, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 19,600 shares of the Company’s common stock at an exercise price per share of $15.77, which was the closing price on December 8, 2023, and

Yahoo | December 11, 2023

We Think Arcus Biosciences (NYSE:RCUS) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 9, 2023

Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data

Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.

Yahoo | December 7, 2023

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.

Yahoo | December 5, 2023

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

ALAMEDA, Calif. & HAYWARD, Calif., December 04, 2023--Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). Exelixis

Yahoo | December 4, 2023

Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

HAYWARD, Calif., November 14, 2023--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference in Miami, FL. The fireside chat will take place on Tuesday, November 28th, 2023 at 7:55am ET.

Yahoo | November 14, 2023

Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Trimmed Their Revenue Forecasts By 17%

One thing we could say about the analysts on Arcus Biosciences, Inc. ( NYSE:RCUS ) - they aren't optimistic, having...

Yahoo | November 12, 2023

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions. [Operator instructions] This call is being recorded and will be available on the investors section of the ARCUS website. I will now […]

Yahoo | November 8, 2023

Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update

HAYWARD, Calif., November 07, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers.

Yahoo | November 7, 2023

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

FOSTER CITY, Calif. & HAYWARD, Calif., November 06, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study. This ongoing Phase 2, multi-arm, global study is evaluating the safety and efficacy of various combinations of the Fc-silent

Yahoo | November 6, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!